Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial

Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData

The approval marks a significant milestone for the American pharmaceutical company in the field of UC

Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer

Dabur India expects mid-single digit revenue growth in Q4

International Business is expected to register double-digit growth in constant currency terms

Max CMD Abhay Soi is new president of NATHEALTH

New leadership team announced at NATHEALTH Annual General Meeting 2024

Colgate Active Salt redefines oral hygiene with a new and improved formula

Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus

Apotex to acquire Canadian Searchlight Pharma

Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals

Vivity reaches 1 million milestone

Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology

Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours